{"id":338,"date":"2025-09-17T08:50:20","date_gmt":"2025-09-17T08:50:20","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=338"},"modified":"2025-09-17T09:10:42","modified_gmt":"2025-09-17T09:10:42","slug":"china-bd-2025-maxwell-and-kalexo-enters-license-on-sirna-program-2mw7141","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/338.html","title":{"rendered":"[China BD 2025] Mabwell and Kalexo enters License on siRNA Program 2MW7141"},"content":{"rendered":"\n<p>Announced Date: 2025-09-17 (September 17, 2025)<\/p>\n\n\n\n<p>Asset Name: 2MW7141<\/p>\n\n\n\n<p>Licensor (Seller): Mabwell Bio (China)<\/p>\n\n\n\n<p>Licensee (Buyer): &nbsp;Kalexo Bio (US)  &lt;by Aditum Bio Fund 3, L.P. &gt;<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: SiRNA<\/p>\n\n\n\n<p>Asset Target: undisclosed<\/p>\n\n\n\n<p>Potential Indication: Management of dyslipidaemias<\/p>\n\n\n\n<p>Current Stage: preclinical<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority: <\/p>\n\n\n\n<p>Mabwell will grant Kalexo Bio the exclusive global rights to develop, manufacture, and commercialize 2MW7141.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Mabwell will receive an upfront payment and near term payment of\u00a0$120 million\uff0c<\/p>\n\n\n\n<p>Mabwell may receive equity of Kalexo Bio.<\/p>\n\n\n\n<p>Eligible to receive potential milestone payment up to\u00a0$1 billion.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Mabwell  \u8fc8\u5a01\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-09-17 (September 17, 2025) Asset Name: 2MW7141 Licensor (Seller): Mabwell Bio (China) Licensee (Buyer): &hellip; <a title=\"[China BD 2025] Mabwell and Kalexo enters License on siRNA Program 2MW7141\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/338.html\"><span class=\"screen-reader-text\">[China BD 2025] Mabwell and Kalexo enters License on siRNA Program 2MW7141<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,5],"tags":[],"class_list":["post-338","post","type-post","status-publish","format-standard","hentry","category-china-license-out","category-newco"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=338"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/338\/revisions"}],"predecessor-version":[{"id":341,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/338\/revisions\/341"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}